The present study is a double-blind clinical trial study, which was carried out from April to August 2014 in Tehran, Iran. This study was approved by the Ethics Committee of Shahid Beheshti University of Medical Sciences, number PHARMACY.SBMU1392, and registered in the Clinical Trials Center, number IRCT201206104317N7. Besides, the ethical considerations were applied according to the revised Helsinki Statement 2013 (
21).
Sampling in this study was purposive firstly, and encompassed all women who were referred to the selected health centers (8 centers) at the time of the study with a diagnosis of vaginitis. The inclusion criteria were those who married with the age range of 15 - 45 years; not being in pregnancy, breastfeeding, or prematurely menopausal periods; no abnormal vaginal bleeding and chronic diseases; no history of taking antibiotics in the last 2 weeks; not using birth control pills or IUDs; not using herbal or chemical medicines to treat vaginitis in the last 2 weeks; and no allergy to herbal medicines. Exclusion criteria were drug-related allergies or illnesses, not taking more than 1 dose of the drug, and having sex without a condom during the treatment. For any reason, no willingness to continue the treatment. Sample size in this study was calculated by mean differences formula, power of test 0.90 and effect size 0.60, type 1 error 0.05; finally, 60 patients were determined for each group (
13).
A questionnaire of personal and midwifery characteristics and a checklist for recording vaginitis signs were made by a researcher based on referenced documents and different articles. Content validity of the instruments was done by 15 professors of Midwifery and Reproductive Health, Pharmacy, and Laboratory Sciences at Shahid Beheshti University of Medical Sciences. Reliability tests are not indicated for demographic questionnaires and this type of checklist. Women who met the inclusion criteria completed a questionnaire and a checklist. The sterile speculum was then placed in the vagina without impregnation with a substance to confirm the presence of a candidate infection. A sample of secretions from the upper part of the vaginal wall was then removed with 3 sterile cotton swabs. The first swap was applied to the slide by adding normal saline. To examine the secretions for fungal elements, 10% potassium hydroxide was poured on the second slide and the second swab was drawn on it. Both slides were examined under a microscope (Nikon-Japan) with a magnification of 10 - 40 X. If key cells or flagellate parasites were observed on the first slide, they were diagnosed with Gardenela or Trichomonas and prescribed appropriate treatment by a gynecologist. If blastopores mycelium was observed on the second slide, the presence of Candida was confirmed. If the smear was positive for Candida, pH paper (Merck KGaA, 64271 Darmstadt, Germany) was used. If the pH was 4 - 4.5, it was recorded as a positive candidate and if the pH was high due to mixed infection, it was excluded from the study, and appropriate treatment was prescribed. If the smear is positive for Candida, for the final diagnosis of the third swab, it is transferred to Cio dextrose agar (Dandurand 2331, Montreal, Canada H5G 3C5) and sent by the researcher to the hospital laboratory. The samples were incubated at a temperature of 30 - 37°C, and the formed colonies were evaluated by a laboratory doctor after 48 - 72 hours. Samples for which this diagnosis was finalized (more than 10 colonies per sterile swap) were coded as definitive samples and entered into the study after approval by a gynecologist. Then, the coded subjects were randomly allocated to 2 groups: Clotrimazole and placebo capsule; and clotrimazole with oral cinnamon capsule by the researcher using excel software (random digit table).
Cinnamon capsules in this study were prepared by a pharmacognosist in the laboratory of the Faculty of Pharmacy of Shahid Beheshti University of Medical Sciences in Tehran in the form of 500 mg capsules. The researcher instructed the samples to consume 2.5 g daily (1 g in the morning, 1 g at noon, and 0.5 g at night) for 7 days. The placebo capsule containing 500 mg of starch was prepared in the same color and shape as the cinnamon capsule, and cinnamon was prescribed in the same way. Because of the inherent aroma of cinnamon capsules, placebo capsules were placed next to them so that they could not be detected. Capsules were packed by a pharmacognosist at box A and B separately, and then according to random numbering, allocated to each group. For randomized allocating participants to groups, a random digit table was used by excel software. Consumption of 1 applicator of clotrimazole 1% vaginal cream (10 μg/mL), made by Behvarzan company, was prescribed for both groups every night for a week. The researcher asked all the samples to come to the clinic on the 7th day and 2nd month after the treatment to complete the checklist by the gynecologist and researcher.
All participants had to have a vaginal smear for microscopic examination before treatment, and 7th day after treatment. The researcher asked all the samples about the side effects of taking the drug. All samples were given medication instructions orally, and health advice was given. The participants were advised to refrain from condom-free intercourse, vaginal douches, other vaginal medications, and antibiotics while taking the medication. Otherwise, they would be excluded from the study. If left untreated, the patient would be referred to a gynecologist. It should be noted that telephone access to the researcher and gynecologist was possible for all samples during the study. This clinical trial was double-blinded, so neither researcher nor the samples knew what kind of treatment was prescribed for them.
2.1. Statistical Analysis
For descriptive and analytic statistical analysis, SPSS version 21 was used. t-test, Cochran’s Q test, chi-square (χ2), or Fisher’s exact test were used to compare intergroup changes, and McNemar test was used to compare intragroup changes. P-value < 0.05 was considered statistically significant.